logo-loader
viewErgomed PLC

Ergomed brings in new hire to bolster PrimeVigilance service offering

The AIM-listed company said it had appointed Dr Michael Forstner as head of risk management and pharmacoepidemiology

Handshake
Ergomed said Forstner would help broaden its premium service offering

Ergomed Plc (LON:ERGO) has added specialist pharmacoepidemiology services to its PrimeVigilance drug safety and information offering with a new hire.

The AIM-listed company, which provides specialist services to the pharmaceutical industry, said it had appointed Dr Michael Forstner as head of risk management and pharmacoepidemiology.

READ: Ergomed sees strong rise in backlog of contracted revenue

The group added that the ongoing contracts of Mesama Consulting, a Swiss-based consultancy founded in 2011 by Professor Jan-Willem van der Velden and most recently owned and managed by Forstner, would be assigned to PrimeVigilance.

Ergomed said Frostner is an expert in pharmacovigilance with significant experience in the planning, development, implementation and evaluation of risk management strategies, including post-authorisation studies, supporting the safe use of medicinal products.

They added that his skills would broaden Ergomed's premium service offering within PrimeVigilance, and build new revenue streams in pharmacoepidemiology and risk minimisation services, meeting high demand.

Stephen Stamp, Ergomed chief executive, said: "I am delighted to welcome Michael to Ergomed with his significant experience in PV services, in addition to his unique expertise in pharmacoepidemiology and risk management strategies.

He added: “His appointment will add value to our PrimeVigilance services as well as providing a bridge between CRO and PV, which fits perfectly in our strategy to leverage our expertise in pharmacovigilance and late phase clinical research, and build a new revenue stream in both our PV and specialist CRO services. We remain focused on growing both of our service offerings organically and through strategic acquisitions."

In mid-morning trading Friday, Ergomed shares were up 2.6% at 235p.

--Adds share price--

Quick facts: Ergomed PLC

Price: 430 GBX

AIM:ERGO
Market: AIM
Market Cap: £205.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

2 min read